Background: Pharmacologic strategies are often required to help manage agitated patients with delirium. First-and second-generation antipsychotic medications (such as haloperidol, quetiapine, and olanzapine) are commonly used.
Objective: On the psychiatric consultation service in our hospital, thiothixene has been used based on its favorable potency, sedative, and cost profiles. Little has been written about the utility of this drug for management of delirium.
Methods: We reviewed our experience with thiothixene in this setting using pharmacy records to identify patients who received at least 1 dose between July 2011 and March 2014. We scrutinized the relevant medical records (n = 111) and recorded the following data: age, sex, medical diagnoses, signs and symptoms of delirium, dosing of thiothixene, and response to thiothixene in terms of both apparent benefit as well as side effects.
Results: Resolution or improvement was documented in 78% of patients and good tolerability in 82% of patients.
Conclusions: Although further data from a randomized, controlled trial would be ideal, our experience suggests that thiothixene could be a safe and effective pharmacologic treatment for agitation and psychosis due to delirium.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.psym.2015.02.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Determining Ideal Management for Patients With Coexisting Prolactinomas and Psychiatric Symptoms: A Systematic Review.
J Psychiatr Pract
May 2024
Department of Obstetrics, Gynecology, and Women's Health-Repo Endocrinology, Division of Reproductive Endocrinology and Infertility, School of Medicine, Saint Louis University Saint Louis, MO.
Objective: Prolactinomas-pituitary tumors that overproduce prolactin-can cause various troublesome symptoms. Dopamine agonists (DAs) reduce prolactin production in the prolactin pathway, making them the first-line treatment for prolactinomas. However, the main side effect of DA treatment, hyperdopaminergia, is an explicit etiology for psychiatric side effects.
View Article and Find Full Text PDFWithdrawal syndrome after antipsychotics discontinuation: an analysis of the WHO database of spontaneous reports (Vigibase) between 2000 and 2022.
Psychopharmacology (Berl)
June 2024
Department of Medical and Clinical Pharmacology, Centre of PharmacoVigilance and Pharmacoepidemiology, Faculty of Medicine and Toulouse University Hospital (CHU), 37 Allées Jules-Guesde 31000, Toulouse, France.
Article Synopsis
- Withdrawal syndrome (WDS) may occur after stopping antipsychotic medications, potentially due to increased dopamine activity, especially with drugs closely binding to D2 receptors.* ! -
- Analysis of pharmacovigilance data revealed that insomnia, anxiety, and depression were common withdrawal symptoms, with tiotixene showing the highest risk of WDS among antipsychotics studied.* ! -
- The study found a weak correlation between the binding affinity of D2/5HT2A receptors and WDS risk, indicating that not all antipsychotics carry the same withdrawal risk, with some like chlorpromazine being safer.* !
First generation antipsychotic-associated serious adverse events in women: a retrospective analysis of a pharmacovigilance database.
Int J Clin Pharm
April 2024
Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Binghamton University, 96 Corliss Avenue, Johnson City, NY, 13790, USA.
Article Synopsis
- Women are under-represented in antipsychotic medication trials, leading to a study that evaluates five adverse events (AE) of first-generation antipsychotics (FGAs) using the FDA Adverse Event Reporting System (FAERS).
- The study analyzed 24.6 million AE reports since 2000 and found varying reporting odds ratios (ROR) for different AEs between men and women, highlighting significant differences, especially for tardive dyskinesia (TD) and agranulocytosis (AG).
- The results indicate that women may face increased risks of severe outcomes related to FGAs, particularly for TD hospitalization and AG-related deaths, as well as a notable increased risk for Torsades de Pointes (
Effects of antipsychotics on heart rate in treatment of schizophrenia: a systematic review and meta-analysis.
Ther Adv Psychopharmacol
June 2022
Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, München, Germany.
Background: Antipsychotics are the treatment of choice in the therapy of schizophrenia. These drugs can be associated with changes in heart rate, but this question has never been examined systematically.
Objective: We aimed to analyse changes in heart rate during treatment with antipsychotics using the frequency of tachycardia and bradycardia events.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!